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Introduction {#s1}
============

Sulfotransferase (SULT) enzymes catalyze the sulfate conjugation of a broad range of substrates and play an important role in metabolism of endogenous and exogenous compounds including thyroid and steroid hormones, neurotransmitters, drugs and procarcinogens [@pone.0106774-Coughtrie1], [@pone.0106774-Richard1]. There are many isoforms of the *SULT*s supergene family, each with different amino acid sequence identity and substrate specificity [@pone.0106774-Glatt1]. SULT1A1 is an important member of the sulfotransferase family involving in the pathogenic process of various cancers [@pone.0106774-Glatt1]--[@pone.0106774-Glatt2].

The *SULT1A1* gene is located on chromosome 16p12.1--p11.2 [@pone.0106774-Dooley1]. Previous study indicated that exon 7 of the *SULT1A1* gene contained a G to A transition at codon 213 (rs9282861) that causes an Arg to His amino acid substitution [@pone.0106774-Raftogianis1]. Some studies have shown that this genetic polymorphism leads to a decrease in enzymatic activity of SULT1A1 and the sulfonation efficiency thus associating with susceptibility to several cancers [@pone.0106774-Nagar1], [@pone.0106774-Ozawa1]. Although the specific role of *SULT1A1* Arg213His polymorphism in carcinogenesis has been investigated in numerous case-control studies, the results have been inconclusive, even conflictive. In order to give a comprehensive and precise result, we performed this meta-analysis study to analyze the association between this polymorphism and cancer risk.

Materials and Methods {#s2}
=====================

Identification of eligible studies {#s2a}
----------------------------------

The meta-analysis was conducted following the criteria of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ([Checklist S1](#pone.0106774.s004){ref-type="supplementary-material"}). In this study, we did an exhaustive literature search on studies that examined the association of the *SULT1A1* gene polymorphisms with cancer risks. All eligible studies were identified by searching the following databases: PubMed, Web of Knowledge and China National Knowledge Infrastructure (CNKI, <http://www.cnki.net/>). The following terms were utilized: "sulfotransferase, *SULT* or *SULT1A1*", "polymorphism, variation, variant or mutation" and "cancer or carcinoma". In the CNKI database, we searched with these corresponding key words in Chinese characters. Included studies should meet the following criteria: (1) evaluating the association between *SULT1A1* Arg213His polymorphism and cancer risk; (2) study designed as case-control; (3) sufficient data available to estimate an odd ratio (OR) with its 95% confidence interval (95% CI).

Data extraction {#s2b}
---------------

Two investigators extracted data independently and reached consensus on the following characteristics of the selected studies: first author\'s name, the year of publication, ethnicity of the study population, matching criteria, number of participants, genotype distribution and control source.

Statistical analysis {#s2c}
--------------------

Hardy-Weinberg equilibrium was assessed by Chi-square test. Crude odd ratio (OR) and 95% confidence interval (CI) were used to estimate the association between *SULT1A1* polymorphism and cancer susceptibility under the dominant model (Arg/His+His/His vs. Arg/Arg), recessive model (His/His vs. Arg/Arg~+~Arg/His), homozygous model (His/His vs. Arg/Arg), heterozygous model (His/Arg vs. Arg/Arg) and allelic model (His vs. Arg). The heterogeneity among the studies was evaluated by Q-test and *I^2^* value ranging from 0% to 100% to describe the percentage of between-study variation caused by heterogeneity. P value for the Q-test less than 0.10 indicates existing heterogeneity among studies. And then the pooled OR was measured by a random effect model (the DerSimonian-Laird method). Otherwise, a fixed effect model (the Mantel-Haenszel method) was chosen.

Subgroup analyses were performed according to cancer type (breast cancer, colorectal cancer, urothelial cancer, prostate cancer, lung cancer, upper aero digestive tract (UADT) cancer, ovarian cancer and gastric cancer), ethnicity (Caucasian, East Asian, Indian and African) and source of controls (hospital based and population based). When heterogeneity was detected, a multivariable meta-regression analysis including cancer type, ethnicity, control source and year of publication to explore potential source of heterogeneity and sensitivity analysis were performed.

The potential publication bias was estimated using Egger\'s linear regression test by visual inspection of the funnel plot. P~\<~0.05 was considered statistically significant, and all P values were two-sided. Analyses were performed using the software Review Manager 5.3 (Cochrane Collaboration), R software ([www.r-project.org](http://www.r-project.org)) and STATA 12.0 software (StataCrop).

Results {#s3}
=======

Characteristics of eligible studies {#s3a}
-----------------------------------

The flow diagram of literature search was given in [Figure 1](#pone-0106774-g001){ref-type="fig"}. A total of 91 studies focusing the association between the *SULT1A1* Arg213His polymorphism and cancer risks were identified. 25 of them were ruled out because of unavailable data or repeated data. Thus, the allele and genotype frequencies of the *SULT1A1* Arg213His polymorphism were extracted from 66 articles. However, 18 articles didn\'t meet with Hardy-Weinberg equilibrium and were abandoned ([Excluded list S1](#pone.0106774.s005){ref-type="supplementary-material"}). As a result, 53 studies of 48 articles, involving 16733 cases and 23334 controls were included in the pooled analyses [@pone.0106774-Arslan1]--[@pone.0106774-Feng1].

![Flow diagram of the study selection process.](pone.0106774.g001){#pone-0106774-g001}

The characteristics of studies included in the current meta-analysis are shown in [Table 1](#pone-0106774-t001){ref-type="table"}. Among these studies, 13 were conducted for breast cancer, 10 for colorectal cancer, 7 for urothelial cancer, 5 for prostate cancer, 5 for lung cancer, 5 for UADT (upper aero digestive tract) cancer, 3 for ovarian cancer, 2 for gastric cancer and 1 for myeloid leukemia, multiple myeloma, and endometrial cancer, respectively. By ethnics, there were 27 studies of Caucasians, 11 studies of East Asians, 4 studies of Indians, 2 studies of Africans and 9 studies of mixed ethnics. By source of controls, 16 studies were population-based, 17 studies were hospital-based and 20 studies were not clear.

10.1371/journal.pone.0106774.t001

###### Characteristics of studies included in the meta-analysis.
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  First author     Year     Cancer type       Ethnicity    Source of Control   Sample Size (Case/Control)   Genotype Distribution (Case/Control)   P for *HWE*            
  --------------- ------ ------------------ ------------- ------------------- ---------------------------- -------------------------------------- ------------- --------- -------
  Seth             2000        Breast         Caucasian       Population                444/227                           229/110                    176/94       39/23    0.907
  Steiner          2000       Prostate        Caucasian       Population                134/184                            57/72                      60/80       17/32    0.496
  Bamber           2001      Colorectal       Caucasian          Mixed                  226/293                            96/137                    104/124      26/32    0.885
  Wang             2001         Lung          Caucasian       Population                463/485                           195/226                    201/196      67/63    0.148
  Zheng            2001        Breast           Mixed         Population                155/328                            55/148                    71/136       29/44    0.368
  Nowell           2002      Colorectal         Mixed         Population                130/301                            48/101                    67/145       15/55    0.973
  Ozawa            2002      Urothelial      East Asians      Population                166/214                           128/154                     32/53        6/7     0.662
  Sachse           2002      Colorectal       Caucasian       Population                490/593                           217/275                    209/255      64/63    0.944
  Wong             2002      Colorectal       Caucasian         Unknown                 383/402                           175/178                    179/190      29/34    0.239
  Wu               2003         UADT         East Asians       Hospital                 187/308                           135/274                     52/34        0/0     0.591
  Tang             2003        Breast           Mixed           Unknown                 103/133                            50/79                      42/47       11/7     1.000
  Tsukino          2003      Urothelial      East Asians       Hospital                 306/306                           238/242                     62/60        6/4     0.992
  Zheng            2003      Urothelial         Mixed          Hospital                 384/386                           196/164                    155/174      33/48    0.985
  Chacko           2004        Breast           India          Hospital                 140/140                            76/95                      56/41        8/4     0.986
  Hung             2004      Urothelial       Caucasian        Hospital                 201/214                           121/116                     72/88       8/10     0.422
  Langsenlehner    2004        Breast         Caucasian       Population                498/499                           201/224                    250/212      47/63    0.515
  Liang            2004         Lung         East Asians      Population                805/809                           581/672                    217/134       7/3     0.397
  Nowell           2004       Prostate         African        Population                 106/93                            59/46                      42/41        5/6     0.732
  Nowell           2004       Prostate        Caucasian       Population                344/310                           149/109                    149/145      46/56    0.815
  Cheng            2005        Breast        East Asians       Hospital                 468/740                           439/693                     27/47        2/0     0.672
  Jerevall         2005        Breast         Caucasian       Population                229/227                            80/83                     121/106      28/38    0.916
  Lilla            2005        Breast         Caucasian       Population                419/884                           198/374                    169/403     52/107    0.995
  Pereira          2005      Colorectal         Mixed           Unknown                  42/100                            15/45                      23/44       4/11     0.999
  Pereira          2005       Gastric           Mixed           Unknown                  20/100                            10/45                      8/44        2/11     0.999
  Pereira          2005   Myeloid leukemia      Mixed           Unknown                  35/100                            14/45                      16/44       5/11     0.999
  Pereira          2005   Multiple myeloma      Mixed           Unknown                  28/100                             7/45                      15/44       6/11     0.999
  Sellers          2005        Ovary          Caucasian        Hospital                 454/542                           197/236                    194/237      63/69    0.735
  Sillanpaa        2005        Breast         Caucasian       Population                480/478                           145/147                    229/221     106/110   0.313
  Sun              2005      Colorectal       Caucasian       Population                109/666                            43/266                    27/303       39/97    0.778
  Boccia           2006         UADT          Caucasian        Hospital                 123/247                            71/156                     44/82        8/9     0.907
  Chen             2006      Colorectal      East Asians      Population                 83/343                            67/301                     15/41        1/1     0.950
  Feng             2006         UADT         East Asians       Hospital                 163/166                           109/129                     50/32        4/5     0.258
  Boccia           2007       Gastric         Caucasian        Hospital                 107/254                            57/156                     39/85       11/13    0.950
  Holt             2007        Ovary           African        Population                 33/127                            21/67                      10/48       2/12     0.735
  Holt             2007        Ovary          Caucasian       Population                277/448                           117/185                    133/213      27/50    0.624
  Lilla            2007      Colorectal       Caucasian       Population                504/603                           212/263                    225/259      67/81    0.404
  Roupret          2007      Urothelial       Caucasian        Hospital                 268/268                           119/140                    99/101       50/27    0.395
  Hirata           2008     Endometrial       Caucasian        Hospital                 150/165                            68/103                     59/52       23/10    0.619
  Koike            2008       Prostate       East Asians       Hospital                 126/119                            94/85                      32/32        0/2     0.875
  Wang             2008      Urothelial      East Asians       Hospital                 300/300                           261/240                     37/54        2/6     0.377
  Arslan           2009         Lung          Caucasian       Population                106/271                            50/162                     52/99       4/10     0.554
  Cleary           2010      Colorectal       Caucasian       Population               1164/1292                          544/598                    502/540     118/154   0.173
  MERIE-GENICA     2010        Breast         Caucasian       Population               3139/5426                         1381/2338                  1332/2430    426/658   0.789
  Syamala          2010        Breast           India         Population                359/367                           254/271                     87/90       18/6     0.894
  Arslan           2011       Prostate        Caucasian       Population                104/151                            55/91                      38/54       11/6     0.846
  Ihsan            2011         Lung            India         Population                188/290                           123/153                    50/116       15/21    0.988
  Serrano          2011        Breast         Caucasian        Hospital                  46/136                            24/71                      18/55       4/10     0.989
  Tamaki           2011         Lung         East Asians       Hospital                 192/203                           120/132                     70/68        2/3     0.211
  Cui              2012      Urothelial      East Asians       Hospital                 282/257                           218/201                     59/52        5/4     0.956
  Eichholzer       2012      Colorectal       Caucasian       Population                424/819                           183/389                    193/354      48/76    0.940
  Khvostova        2012        Breast         Caucasian       Population                335/530                            47/166                    164/261     124/103   1.000
  Kotnis           2012         UADT            India           Unknown                 109/194                            60/132                     43/60        6/2     0.232
  Santos           2012         UADT            Mixed          Hospital                 202/196                            94/94                      89/82       19/20    0.944

*HWE*, Hardy-Weinberg equilibrium.

Overall Analysis {#s3b}
----------------

[Table 2](#pone-0106774-t002){ref-type="table"} showed the results of overall analysis and the subgroup analysis. The analyses on the full data set indicated a significant association of the *SULT1A1* Arg213His polymorphism with cancer risk: heterozygous (OR = 1.09, 95% CI = 1.01--1.19, P = 0.035), homozygous (OR = 1.20, 95% CI = 1.04--1.39, P = 0.014), dominant (OR = 1.12, 95% CI = 1.03--1.22, P  =  0.008) ([Figure S1](#pone.0106774.s001){ref-type="supplementary-material"}), recessive (OR = 1.16, 95% CI = 1.02--1.32, P = 0.027) and allelic model (OR = 1.11, 95% CI = 1.04--1.20, P = 0.003), with high heterogeneity among studies (*I^2^* = 63.1%, 62.6%, 68.5%, 58.3% and 73.7%, respectively, all P\<0.001)([Table 3](#pone-0106774-t003){ref-type="table"}).

10.1371/journal.pone.0106774.t002

###### Overall and subgroup meta-analysis of the association between *SULT1A1* Arg213His polymorphism and cancer risk under genetic models.
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  Groups                    N    Cases/Controls       Heterozygous       Homozygous         Dominant         Recessive         Allelic                                                                       
  ------------------------ ---- ---------------- ---------------------- ------------ ---------------------- ----------- ---------------------- ------- ---------------------- ------- ---------------------- -------
  **Total**                 53    16733/23334     1.09 \[1.01, 1.19\]a     0.035      1.20 \[1.04, 1.39\]a     0.014     1.12 \[1.03, 1.22\]a   0.008   1.16 \[1.02, 1.32\]a   0.027   1.11 \[1.04, 1.20\]a   0.003
  **Cancer type**                                                                                                                                                                                            
  Breast cancer             13     6815/10115     1.14 \[0.97, 1.33\]a     0.108      1.37 \[1.01, 1.87\]a     0.045     1.18 \[1.00, 1.40\]a   0.050   1.23 \[0.96, 1.57\]a   0.108   1.15 \[1.00, 1.32\]a   0.044
  Colorectal cancer         10     3555/5412      1.05 \[0.95, 1.15\]b     0.354      1.13 \[0.88, 1.45\]a     0.352     1.06 \[0.97, 1.15\]b   0.224   1.13 \[0.83, 1.52\]a   0.439   1.08 \[0.97, 1.19\]a   0.169
  Urothelial cancer         7      1907/1945      0.86 \[0.74, 1.00\]b     0.050      0.97 \[0.56, 1.71\]a     0.925     0.88 \[0.71, 1.10\]a   0.269   1.03 \[0.63, 1.69\]a   0.907   0.92 \[0.73, 1.16\]a   0.475
  Prostate cancer           5       814/857       0.87 \[0.70, 1.07\]b     0.188      0.82 \[0.44, 1.51\]a     0.515     0.85 \[0.69, 1.03\]b   0.097   0.79 \[0.58, 1.08\]b   0.145   0.86 \[0.74, 1.00\]b   0.051
  Lung cancer               5      1754/2058      1.19 \[0.79, 1.80\]a     0.404      1.19 \[0.87, 1.63\]b     0.269     1.21 \[0.82, 1.79\]a   0.344   1.15 \[0.85, 1.56\]b   0.357   1.18 \[0.88, 1.58\]a   0.279
  UADT cancer               5       784/1111      1.62 \[1.11, 2.35\]a     0.012      1.39 \[0.85, 2.26\]b     0.185     1.63 \[1.13, 2.35\]a   0.009   1.28 \[0.80, 2.05\]b   0.307   1.52 \[1.10, 2.11\]a   0.012
  Ovarian cancer            3       764/1117      0.96 \[0.79, 1.17\]b     0.697      0.97 \[0.72, 1.32\]b     0.857     0.96 \[0.80, 1.16\]b   0.695   0.99 \[0.74, 1.32\]b   0.944   0.98 \[0.85, 1.12\]b   0.746
  Gastric cancer            2       127/354       1.16 \[0.75, 1.80\]b     0.510      1.81 \[0.86, 3.81\]b     0.12      1.26 \[0.84, 1.91\]b   0.264   1.73 \[0.84, 3.57\]b   0.139   1.29 \[0.93, 1.78\]b   0.126
  **Ethnicity**                                                                                                                                                                                              
  Caucasian                 27    11621/16614     1.06 \[0.97, 1.16\]a     0.174      1.20 \[1.01, 1.43\]a     0.035     1.10 \[1.00, 1.20\]a   0.044   1.16 \[0.99, 1.36\]a   0.058   1.10 \[1.01, 1.19\]a   0.019
  East Asian                11     3078/3765      1.22 \[0.92, 1.61\]a     0.175      1.12 \[0.71, 1.79\]b     0.626     1.21 \[0.92, 1.61\]a   0.176   1.10 \[0.69, 1.75\]b   0.697   1.18 \[0.92, 1.52\]a   0.187
  Indian                    4       796/991       1.09 \[0.66, 1.80\]a     0.748      2.25 \[0.94, 5.37\]a     0.067     1.19 \[0.72, 1.96\]a   0.500   1.93 \[1.22, 3.07\]b   0.005   1.25 \[0.84, 1.85\]a   0.274
  African                   2       139/220       0.75 \[0.47, 1.21\]b     0.239      0.60 \[0.23, 1.58\]b     0.299     0.73 \[0.46, 1.15\]b   0.173   0.68 \[0.26, 1.75\]b   0.420   0.77 \[0.53, 1.11\]b   0.158
  **Source of controls**                                                                                                                                                                                     
  Hospital based            17     3895/4718      1.17 \[1.00, 1.38\]a     0.056      1.38 \[1.12, 1.68\]b     0.002     1.21 \[1.02, 1.43\]a   0.029   1.31 \[1.08, 1.59\]b   0.006   1.19 \[1.03, 1.38\]a   0.020
  Population based          16     8295/12176     0.94 \[0.85, 1.03\]a     0.200      0.98 \[0.83, 1.17\]a     0.855     0.96 \[0.91, 1.02\]b   0.162   1.02 \[0.85, 1.24\]a   0.825   0.98 \[0.90, 1.06\]a   0.584

N: total number of studies involved in the analysis; a: random effect model; b: fix effect model.

10.1371/journal.pone.0106774.t003

###### The overall and subgroup heterogeneity test of the *SULT1A1* Arg213His polymorphism on cancer risk.
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  Groups                    Heterozygous   Homozygous   Dominant   Recessive   Allelic                                
  ------------------------ -------------- ------------ ---------- ----------- --------- ------- ------ ------- ------ -------
  **Total**                     63.1         0.000        62.6       0.000      68.5     0.000   58.3   0.000   73.7   0.000
  **Cancer type**                                                                                                     
  Breast cancer                 67.1         0.000        79.4       0.000      75.9     0.000   72.7   0.000   80.7   0.000
  Colorectal cancer             16.4         0.354        58.2       0.010      0.00     0.659   74.0   0.000   50.8   0.032
  Urothelial cancer             20.6         0.272        62.7       0.013      57.9     0.027   54.0   0.042   73.0   0.001
  Prostate cancer               0.00         0.719        53.8       0.070      12.9     0.332   45.8   0.117   47.5   0.107
  Lung cancer                   86.2         0.000        0.00       0.665      85.8     0.000   0.00   0.841   83.0   0.000
  UADT cancer                   68.5         0.013        44.9       0.142      69.1     0.012   42.0   0.160   72.1   0.006
  Ovarian cancer                0.00         0.673        0.00       0.562      0.00     0.560   0.00   0.603   0.00   0.460
  Gastric cancer                0.00         0.457        16.8       0.273      0.00     0.325   0.00   0.347   27.9   0.239
  **Ethnicity**                                                                                                       
  Caucasian                     51.5         0.001        72.7       0.000      62.5     0.000   70.9   0.000   74.4   0.000
  East Asian                    77.8         0.000        0.00       0.481      78.8     0.000   0.00   0.547   77.8   0.000
  Indian                        81.9         0.001        62.7       0.045      83.0     0.001   42.6   0.156   81.0   0.001
  African                       0.00         0.724        0.00       0.845      0.00     0.685   0.00   0.882   0.00   0.653
  **Source of controls**                                                                                              
  Hospital based                58.6         0.001        32.4       0.103      64.6     0.000   21.7   0.207   68.0   0.000
  Population based              40.7         0.046        57.4       0.002      31.1     0.114   69.1   0.000   55.7   0.004

Subgroup Analyses {#s3c}
-----------------

We analyzed the association in cancer type subgroup. *SULT1A1* Arg213His polymorphism can increase cancer risks in the following cancer types: breast cancer (homozygous model: OR = 1.37, 95% CI = 1.01--1.87, P = 0.045; dominant model: OR = 1.18, 95% CI = 1.00--1.40, P = 0.050 and allelic model: OR = 1.15, 95% CI = 1.00--1.32, P = 0.044); UADT cancer (heterozygous model: OR = 1.62, 95% CI = 1.11--2.35, P = 0.012; dominant model: OR = 1.63, 95% CI = 1.13--2.35, P = 0.009 and allelic model: OR = 1.52, 95% CI = 1.10--2.11, P = 0.012). Forest plots of breast cancer risk and UADT cancer risk were shown in [Figure 2](#pone-0106774-g002){ref-type="fig"} and [Figure 3](#pone-0106774-g003){ref-type="fig"} separately.

![Forest plot on the association between *SULT1A1* Arg213His polymorphism and breast cancer risk in homozygous model.](pone.0106774.g002){#pone-0106774-g002}

![Forest plot on the association between *SULT1A1* Arg213His polymorphism and UADT cancer risk in dominant model.](pone.0106774.g003){#pone-0106774-g003}

Analyzed by ethnicity, a moderately increased risk was observed in Caucasians (homozygous model: OR = 1.20, 95% CI = 1.01--1.43, P = 0.035 and allelic model: OR = 1.10, 95% CI = 1.01--1.19, P = 0.019) and Indians (recessive model: OR = 1.93, 95% CI = 1.22--3.07, P = 0.005). No significant association was found in other ethnicities in any model.

By control source, significant association was observed in hospital based study, but not the population based study.

Meta-regression analysis {#s3d}
------------------------

To find potential source of heterogeneity, multivariable meta-regression analyses were conducted in total group and subgroups including cancer type, ethnicity, control source and publication year. In the breast cancer subgroup, ethnicity (heterozygous model, P = 0.027; recessive model, P = 0.020) and publication year (heterozygous model, P = 0.019; recessive model, P = 0.012) are significant sources of heterogeneity ([Table S1](#pone.0106774.s002){ref-type="supplementary-material"}). Other variables don\'t affect heterogeneity.

Sensitivity analysis {#s3e}
--------------------

The sensitivity analysis was constructed by repeating the meta-analysis sequentially removing each study. In the recessive model, two studies [@pone.0106774-Khvostova1], [@pone.0106774-Sun2] were found to affect the pooled OR and the heterogeneity when removed. The study conducted by Khvostova was focused on breast cancer and Sun\'s study was focused on colorectal cancer among Caucasians, so further sensitivity analyses were conducted in total data set and breast cancer, colorectal cancer and Caucasian subgroups after removing the two studies ([Table 4](#pone-0106774-t004){ref-type="table"} and [Table S2](#pone.0106774.s003){ref-type="supplementary-material"}). In total group, the heterogeneity was significantly decreased (*I^2^* = 58.2, 42.2, 63.5, 33.1 and 66.4, respectively). In the subgroup sensitivity analyses, removing the two studies can significantly decrease the heterogeneity among studies, most *I^2^* values less than 50%. And this polymorphism didn\'t show any obvious correlation with breast cancer risk ([Figure 4](#pone-0106774-g004){ref-type="fig"}). At last, we conducted the sensitivity analyses on the remaining studies and the result was stable.

![Forest plot on the association between *SULT1A1* Arg213His polymorphism and breast cancer risk in homozygous model omitting Khvostova\'s study.](pone.0106774.g004){#pone-0106774-g004}

10.1371/journal.pone.0106774.t004

###### Meta-analysis in breast, colorectal and Caucasian subgroups after omitting studies of Khvostova and Sun.
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  Groups                   Heterozygous       Homozygous         Dominant         Recessive         Allelic                                                                       
  ------------------- ---------------------- ------------ ---------------------- ----------- ---------------------- ------- ---------------------- ------- ---------------------- -------
  **Total**            1.09 \[1.01, 1.18\]a     0.040      1.10 \[0.97, 1.24\]a     0.131     1.10 \[1.01, 1.19\]a   0.021   1.06 \[0.96, 1.18\]a   0.261   1.08 \[1.02, 1.16\]a   0.015
  **Cancer type**                                                                                                                                                                 
  Breast cancer        1.05 \[0.93, 1.19\]a     0.400      1.11 \[0.91, 1.35\]a     0.312     1.07 \[0.95, 1.20\]a   0.256   1.07 \[0.89, 1.30\]a   0.469   1.06 \[0.97, 1.15\]a   0.219
  Colorectal cancer    1.07 \[0.97, 1.18\]b     0.165      1.00 \[0.86, 1.16\]b     0.997     1.06 \[0.97, 1.16\]b   0.226   0.97 \[0.84, 1.12\]b   0.439   1.02 \[0.96, 1.10\]b   0.439
  **Ethnicity**                                                                                                                                                                   
  Caucasian            1.01 \[0.96, 1.07\]b     0.690      1.07 \[0.94, 1.21\]a     0.308     1.05 \[0.98, 1.13\]a   0.169   1.04 \[0.93, 1.17\]a   0.470   1.05 \[0.98, 1.11\]a   0.160

Publication bias {#s3f}
----------------

Funnel plots and Egger\'s test were carried out to assess publication bias. The shapes of funnel plots indicated no obvious asymmetry ([Figure 5](#pone-0106774-g005){ref-type="fig"}). Egger\'s test found no publication bias in the heterozygous (P = 0.074); homozygous (P = 0.146); dominant (P = 0.076); recessive (P = 0.282) and allelic model (P = 0.081).

![Begg\'s funnel plot of the Egger\'s test for publication bias of SULT1A1 Arg213His polymorphism and cancer risk.\
(A) heterozygous model (B) homozygous model (C) dominant model (D) recessive model The horizontal line in the funnel plot indicates the fixed-effects summary estimate, whereas the sloping lines indicate the expected 95% confidence intervals for a given SE.](pone.0106774.g005){#pone-0106774-g005}

Discussion {#s4}
==========

SULT1A1 enzyme encoded by *SULT1A1* gene plays an important role in xenobiotic metabolism. The Arg213His polymorphism, the most widely studied polymorphism within *SULT1A1* gene, can reduce enzyme activity and thermostability, and consequently results in an individual\'s susceptibility to cancer [@pone.0106774-Nagar1], [@pone.0106774-Ozawa1].

There have been a few meta-analyses focusing on this mutation and cancer risk [@pone.0106774-Li1]--[@pone.0106774-Sun3]. However, most of these analyses were conducted before the year 2012 and a new meta-analysis is needed to give a comprehensive conclusion due to the increasing data of case-control studies.

This present meta-analysis, including 16733 cases and 23334 controls from 53 case-control studies, explored the association between the *SULT1A1* Arg213His polymorphism and cancer risk. This is the largest scale meta-analysis so far. Our results suggested that the *SULT1A1* Arg213His was associated with UADT cancer risk. As the upper aero digestive tract is exposed to numerous potential carcinogens such as phenolic xenobiotics, polycyclic aromatic hydrocarbons and heterocyclic aromatic amines contained in cigarette smoking, environmental pollutants and some food, this result manifests that the mutation within *SULT1A1* causes the low SULT1A1 activity and is associated with high susceptibility to cancers related with environment.

In the sensitivity analyses, the study conducted by Khvostova influences the pooled estimates and the heterogeneity most in breast cancer subgroup. And after removing this study, the significant association between *SULT1A1* Arg213His and breast cancer risk became null ([Figure 2](#pone-0106774-g002){ref-type="fig"} and [Figure 4](#pone-0106774-g004){ref-type="fig"}). We further checked data from Khvostova and observed the percentage of wild homozygous genotype in Khvostova\'s study was obviously lower than that in other studies thus causing great heterogeneity. At last a robust result was achieved and failed to reveal significant association in breast cancer subgroup. This result is similar to Wang, Lee and Jiang [@pone.0106774-Wang3]--[@pone.0106774-Jiang1], but they found a positive association of this polymorphism with breast cancer susceptibility among Asians. While in our meta-analysis, we only recruited one paper focused on breast cancer among Asians because other papers on Asians deviate from *HWE* and were excluded. This is a limitation of this meta-analysis and more independent case-control studies conducted on Asians are needed to conclude a more comprehensive result.

In the ethnic subgroup analysis, we found that the genotype distributions of the SNP site are different in ethnic groups. When calculating the percentage of alleles in every ethnic, we found that His allele in Asians (9.58%) is significantly less than in Caucasians (35.2%). Different ethnicities may have different genetic backgrounds, thus causing different genotype frequencies in Asian and other ethnic groups which may influence cancer susceptibility.

Li and Kotnis have conducted meta-analyses focused on environment-related cancers, such as tobacco-related cancers and found cancer risk could be modulated by interaction between genetic variants and environmental factors [@pone.0106774-Li1], [@pone.0106774-Kotnis2]. As exposed environmental factors are different according to cancer types, for example smoking leads to lung cancer, while the intake of meat influences breast cancer and colorectal cancer [@pone.0106774-Kruk1], [@pone.0106774-Durko1] and our analysis took many kinds of cancer into account, we decided not to include environmental factors. Moreover, the definitions of exposed environmental factors were not consistent in the studies, which could cause great heterogeneity. Our estimates were based on crude OR values, not adjusted OR values, which may yield inaccurate calculation.

There were several sources bringing in heterogeneity, such as study design, age and sex distribution, and ethnicity. Meta-regression analysis was conducted to find source of heterogeneity. In the breast cancer subgroup, publication year could cause great heterogeneity and further attention was paid to years. We found all the recruited studies were carried out before 2005 or after 2010, and there were no studies between 2006 and 2009. The His allele was 29.6% in the studies before 2005 and 33.0% after 2010, which was significantly different (P = 0.02). This may be caused by the different study population, and needs more case-control studies to illustrate.

In conclusion, our meta-analysis suggests that the *SULT1A1* Arg213His polymorphism may contribute UADT cancer risk. As the result was calculated through sampling statics and statistical difference is not the same as clinical difference, the result can be used for clinical reference, not for clinical diagnosis of cancer. Further detailed investigation with larger number of worldwide participants is needed to clarify the role of this polymorphism in cancer risk.
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